Annual Media Conference
4 February 2009

William M. Burns
CEO Roche Pharma



2008 Highlights in Pharma

- **Sales:** increase twice the market growth (+10% vs 5%)[1]
- **Operational excellence:** margin increase by +0.6 %pts
- **Securing our future:**
  - **Major approvals**: Avastin with paclitaxel 1st line mBC (US)[2], Actemra RA (Japan, EU)
  - **Important filings**: Avastin with docetaxel 1st line mBC (EU), Avastin GBM 2nd line[3], MabThera 1st line and relapsed CLL[4] (EU)
  - **Major clinical data:** Avastin mBC (AVADO, RIBBON-1), Xeloda early breast cancer, Tarceva 1st line maintenance NSCLC (SATURN)

12 new phase III projects initiated, of which 3 are NMEs

[1]underlying, ex Tamilfu pandemic, [2] Accelerated approval; [3]GBM=Glioblastoma Multiforme; [4]CLL=Chronic Lymphocytic Leukemia
[5] NSCLC = non-small cell lung cancer
Local sales growth; margin before exceptional items

Pharma Sales 2008

Achieved +10% growth (excluding Tamiflu pandemic), to deliver additional CHF 3.3 bn underlying sales

	2007 CHF m	2008 CHF m	% change in CHF	% change in local	local growth excl. Tamiflu pandemic
Pharmaceuticals	36,783	35,961	-2	+5	+10
Roche Pharma	22,970	22,164	-4	+3	+9
Genentech	10,414	10,461	0	+11	+11
Chugai	3,399	3,336	-2	-4	+4

Roche Pharma: Strong increase in productivity

Our people are making the difference

- Shift of resources to areas of need
- Despite changes, productivity increased per employee

People
Headcount CAGR +2 %
~36,500 FTEs today

Sales
CAGR +13%
~22 Bn CHF today*

Productivity
Sales/ Head CAGR +10 %
~600 kCHF today



* Sales excluding Tamiflu pandemic
CAGR: compound annual growth rate (2004-2008)
Financial data & growth rates at 2008 fx rates

2008: Pharma operating margin further increased



[1] At constant exchange rates

all before exceptional items

Review of core assets by therapeutic area

Outlook, pipeline and future catalysts

Oncology franchise approaches CHF 20 billion in sales



Double-digit growth continues

Europe/RoW

- Continued strong increase in Avastin sales, driven by strong uptake in mCRC and mBC
- Emerging markets contributing to continued growth of MabThera, Herceptin and Tarceva

Japan

- Strong launches of Avastin, Tarceva, and adjuvant Herceptin

All key oncology brands growing double-digit

Three products with sales exceeding CHF 5 billion



Mabthera: Growth mainly from use following 1st l. in iNHL and RA (global RA sales: approx. CHF 800 m)

Avastin: US: Growth driven mostly by uptake in mBC; EU: Strong growth in mCRC and mBC

Herceptin: Penetration in adj BC now 75% in top 5 EU – strong growth in emerging markets (CEMAI etc)

Tarceva: Strong growth in 2nd and 3rd line NSCLC, good uptake in Asia and Japan

Xeloda: Increased use in adj CC and mCRC (both EU and US) continues to drive growth

Inflammation/Autoimmune/Transplantation

MabThera in RA on continued growth path



2008
Overall franchise growing +19 %

MabThera RA
RA sales: ~CHF 800 Mio. vs ~CHF 450 Mio. in 2007 (est.)

Actemra: very encouraging launch in Japan
EU approval Jan 09, US: resubmission Q3 2009

CellCept
Sales: CHF 2.1 bn (+13%)
• Patent expiry: US: May 2009; key EU countries: end-2010

Virology: Pegasys back to growth

Tamiflu in line with expectations



Pegasys

Well-positioned to benefit from the arrival of new antivirals for HCV (both Roche and non-Roche developed), as it is the pegylated interferon of choice for use in studies of virtually all these new agents.

Review of core assets by therapeutic area

Outlook, pipeline and future catalysts

Roche has the strongest patent protected portfolio



Source: IMS Health MIDAS Market Segmentation MAT June 2008, Ethical protected brand sales only.

Strong commitment to innovation: maintaining an unprecedented level

Roche

2008: 12 ph III initiations

- Avastin+Herceptin in HER2+ adj BC
- Pertuzumab+Herceptin in 1st l. HER2+ mBC
- Avastin in 2nd line platinum-sensitive ovarian cancer (Genentech)
- Avastin in GIST (Genentech)
- Avastin in high-risk carcinoid (Genentech)
- Avastin+Herceptin in 1st l. HER2+ mBC (2nd study, E1105)
- Avastin in 1st line mBC with hormonal therapy (Genentech)
- Avastin head and neck cancer (Genentech)
- Actemra in sJIA
- Ocrelizumab in lupus nephritis
- Dalcetrapib (CETPi) in dyslipidemia
- Taspoglutide (GLP-1) in T2D

3 NMEs, 7 line extensions

2009: up to 10 ph. III starts inc:

- T-DM1 in HER2-positive mBC
- Avastin in glioblastoma 1st line
- R7159/GA101 in hematology *
- Actemra in early RA
- Actemra head to head

4 NMEs, 6 line extensions

* Formal decision to move in phase III pending

Pharmaceuticals objectives for 2009

Important clinical trial results and major Phase III initiations

Roche

Major clinical data

Compound	Phase	Indication / data	Timing
Avastin	III	Adj CC NSABP C-08, final analysis	Q2 2009
Avastin	III	1st line mBC (RIBBON-1), full data	H1 2009
Avastin+Tarceva	III	NSCLC 1st line maint (ATLAS), final analysis	H1 2009
Tarceva	III	NSCLC 1st line maint (SATURN), full data	H1 2009
Xeloda	III	Adj CC with oxaliplatin, final analysis	2009
T-DM1	II	Phase III initiation	H1 2009
R7159/GA101	II	Phase III formal decision	2009
IGF-1R	II	Phase III formal decision	2009
Actemra	III	LITHE 2yrs X-ray data	H2 2009
MabThera RA	III	MTX-naive X-ray data (IMAGE)	H1 2009
Aleglitazar	II	Phase III decision	H1 2009

Filings

Compound	Indication
Avastin	1st line mBC (RIBBON-1)
MabThera	CLL relapsed (REACH) ✓
MabThera	RA DMARD IR + MTX-naive (X-ray data)
Tarceva	1st line maint. NSCLC (SATURN)
Tarc.+Avastin	1st line maint. NSCLC (ATLAS)
Xeloda	Adj CC with oxaliplatin, and adj BC

Divisional sales growth

Above-market, mid single-digit in local currencies

barring unforeseen events

Roche

We Innovate Healthcare